Insulin Aspart
Insulin Aspart
Insulin Aspart (pronounced as IN-su-lin AS-part) is a fast-acting insulin analog marketed by Novo Nordisk as a product under the trade name NovoLog/NovoRapid.
Etymology
The term "Insulin Aspart" is derived from the scientific name for the compound, which is B28 aspart insulin. The "aspart" in the name refers to the substitution of the amino acid proline with aspartic acid at position B28 in the insulin molecule.
Pharmacology
Insulin Aspart is a recombinant, biosynthetic, fast-acting insulin analog. It has a faster onset of action compared to regular human insulin. It is produced using recombinant DNA technology, altering the amino acid sequence of standard human insulin to achieve its rapid-acting properties.
Usage
Insulin Aspart is used to improve glycemic control in adults and children with diabetes mellitus.
Related Terms
See Also
External links
- Medical encyclopedia article on Insulin Aspart
- Wikipedia's article - Insulin Aspart
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski